Get the Stockscreener App
1.12
5.66%
0.06
After Hours:
1.12
Elutia Inc stock is traded at $1.12, with a volume of 54,337.
It is up +5.66% in the last 24 hours and up +2.75% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$1.06
Open:
$1.06
24h Volume:
54,337
Relative Volume:
0.17
Market Cap:
$47.92M
Revenue:
$18.89M
Net Income/Loss:
$-20.44M
P/E Ratio:
-1.4219
EPS:
-0.7877
Net Cash Flow:
$-46.69M
1W Performance:
+3.70%
1M Performance:
+2.75%
6M Performance:
+8.74%
1Y Performance:
-59.12%
1-Day Range:
$1.06
$1.12
1-Week Range:
$1.04
$1.18
52-Week Range:
$0.50
$2.99
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.12 | 45.35M | 18.89M | -20.44M | -46.69M | -0.7877 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Earnings Miss: Can Elutia Inc be recession proof2026 Technicals & Verified Momentum Stock Ideas - baoquankhu1.vn
If You Invested $1,000 in Elutia Inc. (ELUT) - Stock Titan
Earnings Beat: Can Elutia Inc generate free cash flow2026 Historical Comparison & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Elutia Inc. (NASDAQ:ELUT) Q4 2025 earnings call transcript - MSN
Elutia (ELUT) Q4 2025 Earnings Call Transcript - AOL.com
Forecast Cut: Is Elutia Inc subject to activist investor interest2026 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Technicals: Is Elutia Inc subject to activist investor interest2026 Price Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 - Bitget
Elutia details tech to address infections in breast reconstruction - Stock Titan
Elutia Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Elutia Warns of Ongoing Nasdaq Delisting Risk Despite Recent Compliance Win - TipRanks
Elutia (ELUT) Grants Stock Options to New Hires - GuruFocus
Elutia announces grants of inducement awards - TipRanks
Exit Recap: Is Elutia Inc subject to activist investor interest2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Elutia 2025 10-K: Revenue $12.3M, EPS (cont. ops) $(15.871)M - TradingView
Elutia (NASDAQ: ELUT) pivots to drug‑eluting biomatrix after asset divestitures - Stock Titan
Achieving Micron-Level Tolerances: CAD Optimization for Sub-10µm 3D Printing - AOL.com
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT) - The Globe and Mail
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Bitget
Elutia markets another product for sale as it pivots to breast reconstruction infection prevention - The Business Journals
Elutia grants 460,000 stock options to 3 new hires at $1.09 - Stock Titan
[Form 4] ELUTIA INC. Insider Trading Activity - Stock Titan
Elutia (ELUT) CEO receives stock from RSU vesting while shares withheld for taxes - Stock Titan
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction - Investing.com Australia
Elutia Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-03-12 - Seeking Alpha
Elutia Reports Strong 2025 Financial Results, Advances NXT-41x for Breast Cancer Surgery, and Closes $88M BioEnvelope Sale to Boston Scientific - Minichart
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ... By GuruFocus - Investing.com Canada
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Grow - GuruFocus
Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team - MSN
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction By Investing.com - Investing.com South Africa
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Elutia Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - Bitget
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady - Investing.com Australia
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady By Investing.com - Investing.com India
Elutia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elutia earnings beat by $1.60, revenue topped estimates - Investing.com Canada
Elutia reports $3.3M Q4 revenue, $70.8M net income on BioEnvelope sale; $44.4M year-end cash - TradingView
ELUTIA ($ELUT) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Elutia Q4 revenue rises on higher cardiovascular product sales - TradingView
ELUT: Q4 2025 revenue up 16% year-over-year; focus shifts to NXT-41x for breast reconstruction - TradingView
Elutia (NASDAQ: ELUT) posts 2025 profit as BioEnvelope sale cuts debt and funds NXT-41 - Stock Titan
ELUT: Q4 net income soared to $70.8M on BioEnvelope sale, with NXT-41x FDA process underway - TradingView
Elutia Inc. Adopts 2026 Inducement Award Plan and Files Form 8-K Disclosure - Minichart
Exploring Elutia's Earnings Expectations - Benzinga
Elutia Inc (ELUT) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Elutia Adopts 2026 Inducement Equity Award Plan - TipRanks
ELUT Board adopts 2026 Inducement Award Plan - TradingView
Elutia (NASDAQ: ELUT) sets 2026 inducement plan for 2,000,000 share awards - Stock Titan
Elutia Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):